Citations

Showing 10 of 108083 citations.

Variability in Lipid Levels and Risk for Cardiovascular Disease: An Electronic Health Record–Based Population Cohort Study
Manemann, Sheila M., Moser, Ethan D. , Roger, Véronique L. , Chamberlain, Alanna M. , Remaley, Alan T. , Decker, Paul A. , Killian, Jill M. , Larson, Nicholas B. , Bielinski, Suzette , Moser, Ethan D , Takahashi, Paul Y. , Roger, Veronique L , Chamberlain, Alanna M , Killian, Jill M , Larson, Nicholas B , Bielinski, Suzette J. , Sauver, Jennifer L. St. , Olson, Janet E. , Decker, Paul A.

Mayo Clinic

Journal of the American Heart Association | March 4, 2023 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/jaha.122.027639 | PMID 36870945 Get It

Background Larger within‐patient variability of lipid levels has been associated with increased risk of cardiovascular disease (CVD); however, measures of lipid variability require ≥3 measurements and are not currently used clinically. We investigated the feasibility of calculating lipid variability within a large electronic health record–based population cohort and assessed associations with incident CVD. Methods and Results We identified all individuals ≥40 years of age who resided in Olmsted County, MN, on January 1, 2006 (index date), without prior CVD, defined as myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or CVD death. Patients with ≥3 measurements of total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, or triglycerides during the 5 years before the index date were retained. Lipid variability was calculated using variability independent of the mean. Patients were followed through December 31, 2020 for incident CVD. We identified 19 652 individuals (mean age 61 years; 55% female), who were CVD‐free and had variability independent of the mean calculated for at least 1 lipid type. After adjustment, those with highest total cholesterol variability had a 20% increased risk of CVD (Q5 versus Q1 hazard ratio, 1.20 [95% CI, 1.06–1.37]). Results were similar for low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol. Conclusions In a large electronic health record–based population cohort, high variability in total cholesterol, high‐density lipoprotein cholesterol, and low‐density lipoprotein cholesterol was associated with an increased risk of CVD, independent of traditional risk factors, suggesting it may be a possible risk marker and target for intervention. Lipid variability can be calculated in the electronic health record environment, but more research is needed to determine its clinical utility.
CHARACTERISTICS AND PREDICTORS OF PATIENTS WITH SEPSIS WHO ARE CANDIDATES FOR MINIMALLY INVASIVE APPROACH OUTSIDE OF INTENSIVE CARE UNIT
Smith, Ryan J. , Lal, Amos , Malinchoc, Michael, Gajic, Ognjen, Lal, Amos , Wahab, Abdul, Flurin, Laure , Dong, Yue , Gajic, Ognjen

Mayo Clinic

Shock | March 4, 2023 | Volume: 59 | Issue: 5 | Pages: 702-707

10.1097/shk.0000000000002112 | PMID 36870069 Get It

ABSTRACT Objective: To identify and describe characteristics of patients with sepsis who could be treated with minimally invasive sepsis (MIS) approach without intensive care unit (ICU) admission and to develop a prediction model to select candidates for MIS approach. Methods: A secondary analysis of the electronic database of patients with sepsis at Mayo Clinic, Rochester, MN. Candidates for the MIS approach were adults with septic shock and less than 48 hours of ICU stay, who did not require advanced respiratory support and were alive at hospital discharge. Comparison group consisted of septic shock patients with an ICU stay of more than 48 hours without advanced respiratory support at the time of ICU admission. Results: Of 1795 medical ICU admissions, 106 patients (6%) met MIS approach criteria. Predictive variables (age >65 years, oxygen flow >4 L/min, temperature <37°C, creatinine >1.6 mg/dL, lactate >3 mmol/L, white blood cells >15 × 109/L, heart rate >100 beats/min, and respiration rate >25 breaths/min) selected through logistic regression were translated into an 8-point score. Model discrimination yielded the area under the receiver operating characteristic curve of 79% and was well fitted (Hosmer-Lemeshow P = 0.94) and calibrated. The MIS score cutoff of 3 resulted in a model odds ratio of 0.15 (95% confidence interval, 0.08–0.28) and a negative predictive value of 91% (95% confidence interval, 88.69–92.92). Conclusions: This study identifies a subset of low-risk septic shock patients who can potentially be managed outside the ICU. Once validated in an independent, prospective sample our prediction model can be used to identify candidates for MIS approach.
Molecular Breast Imaging in the Screening Setting
Smith, Katherine Allen, Hunt, Katie N. , Fowler, Amy M. , Smith, Katherine A, Fowler, Amy M , Smith, Katherine A, Rauch, Gaiane M.

Mayo Clinic

Journal of Breast Imaging | March 4, 2023 | Volume: 5 | Issue: 3 | Pages: 240-247

10.1093/jbi/wbad011 | PMID 38416886 Get It

Abstract Early detection of breast cancer through screening mammography saves lives. However, the sensitivity of mammography for breast cancer detection is reduced in women with dense breast tissue. Imaging modalities for supplemental breast cancer screening include MRI, whole breast US, contrast-enhanced mammography, and molecular breast imaging (MBI). Molecular breast imaging with 99mTc-sestamibi is a functional imaging test to identify metabolically active areas in the breast with positioning analogous to mammography. Since 2011, there have been six large, published studies of screening MBI as a supplement to mammography involving over 6000 women from four different institutions. A multicenter, prospective clinical trial of 3000 women comparing breast cancer detection using screening digital breast tomosynthesis alone or in combination with MBI recently completed enrollment. This review focuses on the current evidence of MBI use for supplemental breast cancer screening, the strengths and limitations of MBI, and recent technological advances.
Personalized risk communication and opioid prescribing in association with nonprescribed opioid use: A secondary analysis of a randomized controlled trial
Tiako, Max Jordan Nguemeni , Shofer, Frances S. , Dolan, Abby , Goldberg, Erica , Rhodes, Karin V. , Bellamkonda, Venkatesh R. , Perrone, Jeanmarie , Cannuscio, Carolyn C. , Rodgers, Melissa A. , Zyla, Michael M , Bell, Jeffrey J , McCollum, Sharon, Schapira, Marilyn M. , Nguemeni Tiako, Max Jordan , Engel-Rebitzer, Eden , Hess, Erik P. , Perrone, Jeanmarie , Becker, Lance B. , Engel‐Rebitzer, Eden , Meisel, Zachary F.

Mayo Clinic

Academic Emergency Medicine | March 4, 2023 | Volume: 30 | Issue: 8 | Pages: 851-858

10.1111/acem.14710 | PMID 36869633 Get It

AbstractBackgroundTo determine the impact of personalized risk communication and opioid prescribing on nonprescribed opioid use, we conducted a secondary analysis of randomized controlled trial participants followed prospectively for 90 days after an emergency department (ED) visit for acute back or kidney stone pain.MethodsA total of 1301 individuals were randomized during an encounter at four academic EDs into a probabilistic risk tool (PRT) arm, a narrative‐enhanced PRT arm, or a general risk information arm (control). In this secondary analysis, both risk tool arms were combined and compared with the control arm. We used logistic regressions to determine associations between receiving personalized risk information, receiving an opioid prescription in the ED, and nonprescribed opioid use in general and by race.ResultsComplete follow‐up data were available for 851 participants; 23.3% (n = 198) were prescribed opioids (34.2% of White vs. 11.6% of Black participants, p < 0.001). Fifty‐six (6.6%) participants used nonprescribed opioids. Participants in the personalized risk communication arms had lower nonprescribed opioid use odds (adjusted odds ratio [aOR] 0.58, 95% confidence interval [CI] 0.4–0.83). Black versus White participants had greater nonprescribed opioid use odds (aOR 3.47, 95% CI 2.05–5.87, p < 0.001). Black participants who were prescribed opioids had a lower marginal probability of using nonprescribed opioids versus those who were not (0.06, 95% CI 0.04–0.08, p < 0.001 vs. 0.10, 95% CI 0.08–0.11, p < 0.001). The absolute risk difference in nonprescribed opioid use for Black and White participants, respectively, in the risk communication versus the control arm, was 9.7% and 0.1% (relative risk ratio 0.43 vs. 0.95).ConclusionsAmong Black but not White participants, personalized opioid risk communication and opioid prescribing were associated with lower odds of nonprescribed opioid use. Our findings suggest that racial disparities in opioid prescribing—which have been previously described within the context of this trial—may paradoxically increase nonprescribed opioid use. Personalized risk communication may effectively reduce nonprescribed opioid use, and future research should be designed specifically to explore this possibility in a larger cohort.
Reply
Abdelmalek, Manal F. , Covic, Lidija , Kuliopulos, Athan , Abdelmalek, Manal

Mayo Clinic

Hepatology | March 4, 2023 | Volume: 77 | Issue: 5 | Pages: E111-E112

10.1097/hep.0000000000000285 | PMID 36869845 Get It

Clinicopathological associations of hemispheric dominance in primary progressive apraxia of speech
Robinson, Carling G. , Utianski, Rene L. , Singh, Neha Atulkumar , Pham, Nha Trang Thu, Ertekin‐Taner, Nilüfer , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Clark, Heather A, Utianski, Rene L , Singh, Neha Atulkumar , Whitwell, Jennifer , Josephs, Keith A , Duffy, Joseph R. , Clark, Heather A., Machulda, Mary M. , Botha, Hugo , Dickson, Dennis W.

Mayo Clinic

European Journal of Neurology | March 4, 2023 | Volume: 30 | Issue: 5 | Pages: 1209-1219

10.1111/ene.15764 | PMID 36869612 Get It

AbstractObjectivePrimary progressive apraxia of speech (PPAOS) is associated with imaging abnormalities in the lateral premotor cortex (LPC) and supplementary motor area (SMA). It is not known whether greater involvement of these regions in either hemisphere is associated with demographics, presenting, and/or longitudinal features.MethodsIn 51 prospectively recruited PPAOS patients who completed [18F]‐fluorodeoxyglucose (FDG) positron emission tomography (PET), we classified patients as left‐dominant, right‐dominant, or symmetric, based on visual assessment of the LPC and SMA on FDG‐PET. SPM and statistical analyses of regional metabolic values were performed. Diagnosis of PPAOS was made if apraxia of speech was present and aphasia absent. Thirteen patients completed ioflupane‐123I (dopamine transporter [DAT]) scans. We compared cross‐sectional and longitudinal clinicopathological, genetic, and neuroimaging characteristics across the three groups, with area under the receiver‐operating curve (AUROC) determined as a measure of effect size.ResultsIn all, 49% of the PPAOS patients were classified as left‐dominant, 31% as right‐dominant, and 20% as symmetric, which was supported by results from the SPM and regional analyses. There were no differences in baseline characteristics. Longitudinally, right‐dominant PPAOS showed faster rates of progression of ideomotor apraxia (AUROC 0.79), behavioral disturbances (AUROC 0.84), including disinhibition symptoms (AUROC 0.82) and negative behaviors (AUROC 0.82), and parkinsonism (AUROC 0.75) compared to left‐dominant PPAOS. Symmetric PPAOS showed faster rates of dysarthria progression compared to left‐dominant (AUROC 0.89) and right‐dominant PPAOS (AUROC 0.79). Five patients showed abnormal DAT uptake. Braak neurofibrillary tangle stage differed across groups (p = 0.01).ConclusionsPatients with PPAOS and a right‐dominant pattern of hypometabolism on FDG‐PET have the fastest rates of decline of behavioral and motor features.
Towards Pattern Recognition with Network Science and Natural Language Processing for Information Retrieval
Garg, Muskan , Kumar, Mukesh , Samanta, Debabrata

Mayo Clinic

Proceedings of the 12th International Conference on Pattern Recognition Applications and Methods | March 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.5220/0011779700003411 Get It

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Jang, Albert , Kendi, Ayse T, Jang, Albert , Kendi, A. Tuba , Sartor, Oliver

Mayo Clinic

Therapeutic Advances in Medical Oncology | March 4, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17588359231157632 | PMID 36895851 Get It

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in current therapies are needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer given its increased expression on the surface of the prostate cancer cells. PSMA small molecule binders include PSMA-617 and PSMA-I&T and monoclonal antibodies such as J591. These agents have been linked to different radionuclides including beta-emitters such as lutetium-177 and alpha-emitters such as actinium-225. The only regulatory-approved PSMA-targeted radioligand therapy (PSMA-RLT) to date is lutetium-177–PSMA-617 in the setting of PSMA-positive metastatic castration-resistant prostate cancer that has failed androgen receptor pathway inhibitors and taxane chemotherapy. This approval was based on the phase III VISION trial. Many other clinical trials are evaluating PSMA-RLT in various settings. Both monotherapy and combination studies are underway. This article summarizes pertinent data from recent studies and provides an overview of human clinical trials in progress. The field of PSMA-RLT is rapidly evolving, and this therapeutic approach will likely play an increasingly important role in the years to come.
Systematic Transmission Electron Microscopy‐Based Identification and 3D Reconstruction of Cellular Degradation Machinery
Neikirk, Kit , Vue, Zer , Katti, Prasanna , Rodriguez, Ben I., Omer, Salem, Shao, Jianqiang, Christensen, Trace , Garza-López, Edgar , Marshall, Andrea G. , Palavicino‐Maggio, Caroline B. , Ponce, Jessica, Alghanem, Ahmad F. , Vang, Larry , Barongan, Taylor , Rodman, Taylor, Stephens, Dominique, Mungai, Margaret , Murray, Sandra , Crabtree, Amber , Pereira, Renata O. , Hinton, Antentor , Glancy, Brian , Abel, E Dale , Hinton, Antentor , Pereira, Renata O , Katti, Prasanna , Murray, Sandra A , Marshall, Andrea G , Beasley, Heather K. , Stephens, Dominique C., Correia, Marcelo , Exil, Vernat , Damo, Steven M. , Glancy, Brian , Abel, E. Dale

Mayo Clinic

Advanced Biology | March 3, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/adbi.202200221 | PMID 36869426 Get It

Abstract Various intracellular degradation organelles, including autophagosomes, lysosomes, and endosomes, work in tandem to perform autophagy, which is crucial for cellular homeostasis. Altered autophagy contributes to the pathophysiology of various diseases, including cancers and metabolic diseases. This paper aims to describe an approach to reproducibly identify and distinguish subcellular structures involved in macroautophagy. Methods are provided that help avoid common pitfalls. How to distinguish between lysosomes, lipid droplets, autolysosomes, autophagosomes, and inclusion bodies are also discussed. These methods use transmission electron microscopy (TEM), which is able to generate nanometer‐scale micrographs of cellular degradation components in a fixed sample. Serial block face‐scanning electron microscopy is also used to visualize the 3D morphology of degradation machinery using the Amira software. In addition to TEM and 3D reconstruction, other imaging techniques are discussed, such as immunofluorescence and immunogold labeling, which can be used to classify cellular organelles, reliably and accurately. Results show how these methods may be used to accurately quantify cellular degradation machinery under various conditions, such as treatment with the endoplasmic reticulum stressor thapsigargin or ablation of the dynamin‐related protein 1.